Volume 26, Number 9—September 2020
Dispatch
Oxacillinase-181 Carbapenemase-Producing Klebsiella pneumoniae in Neonatal Intensive Care Unit, Ghana, 2017–2019
Table
Characteristics of neonates and carbapenemase-producing Klebsiella pneumoniae isolates from Korle-Bu Teaching Hospital, Ghana, 2017–2019*
Patient | Sample | Sex | MOD | DOS | Birthweight, kg | Cubicle | Shared space | Date of isolation | ST | Capsular serotype | Prior AB use | AB use after BSI | DOA, d | Vital status |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
KP007 | Carriage | F | CS | 13 | 1.4 | I | No | 2017 Sep 21 | 17 | KL25 | AMK, CXC | NA | NA | Alive |
KP010 | Carriage | F | CS | 21 | 1.1 | II | No | 2017 Sep 21 | 17 | KL25 | AMK, CXC | NA | NA | Alive |
KP011 | Carriage | M | SVD | 18 | 0.9 | I | No | 2017 Sep 21 | 17 | KL25 | AMK, CXC | NA | NA | Dead |
KP020 | Carriage | F | CS | 43 | 0.8 | II | No | 2017 Sep 21 | 48 | KL62 | AMK, CXC, MEM, CIP, VA | NA | NA | Alive |
KP025 | Carriage | F | SVD | 15 | 1.2 | III | No | 2017 Sep 21 | 17 | KL25 | AMK, CXC | NA | NA | Alive |
KP034 | Carriage | M | CS | 34 | 1.4 | III | Yes | 2017 Sep 21 | 17 | KL25 | AMK, CXC, CIP, MEM | NA | NA | Alive |
KP035 | Carriage | F | CS | 30 | 1.4 | III | Yes | 2017 Sep 21 | 17 | KL25 | No | NA | NA | Alive |
KP036 | Carriage | F | SVD | 36 | 1.3 | III | Yes | 2017 Sep 21 | 17 | KL25 | No | NA | NA | Alive |
KP037 | Carriage | M | SVD | 12 | 2.1 | III | Yes | 2017 Sep 21 | 17 | KL25 | AMK, CXC | NA | NA | Alive |
KP045 | Carriage | F | SVD | 11 | 1.7 | III | No | 2017 Sep 21 | 17 | KL25 | AMK, CXC | NA | NA | NA |
KP047 | Carriage | F | SVD | 4 | 3.9 | III | No | 2017 Sep 21 | 17 | KL25 | AMK, CXC | NA | NA | Alive |
KP052 | Carriage | M | CS | 12 | 3 | III | Yes | 2017 Sep 21 | 17 | KL25 | AMK, CXC | NA | NA | Alive |
KP055 | Carriage | M | CS | 24 | 1.5 | III | Yes | 2017 Sep 21 | 17 | KL25 | AMK, CXC | NA | NA | Alive |
KP056 | Carriage | M | SVD | 17 | 3.2 | III | No | 2017 Sep 21 | 17 | KL25 | AMK, CXC | NA | NA | Alive |
K058 | Carriage | M | SVD | 33 | 1 | I | No | 2017 Sep 21 | 17 | KL25 | AMK, CXC | NA | NA | Alive |
K221 | Carriage | F | SVD | 2 | 1.6 | III | No | 2017 Sep 21 | 17 | KL25 | AMK, CXC | NA | NA | Alive |
KP233 | Carriage | M | SVD | 12 | 3.2 | III | No | 2018 Jan 19 | 17 | KL25 | AMK, CXC | NA | NA | Alive |
KP242 | Carriage | M | SVD | 2 | 3.7 | III | No | 2018 Jan 19 | 17 | KL25 | AMK, CXC | NA | NA | Alive |
KP0033 | Blood | M | SVD | 20 | 2.4 | I | NA | 2017 Oct 5 | 17 | KL25 | AMK, CXC, CAZ | MEM, CIP | 10 | Dead |
KP0455 | Blood | M | SVD | 10 | 3.6 | II | NA | 2018 Jan 5 | 17 | KL25 | AMK, CXC | NA | 12 | Dead |
KP0457 | Blood | F | SVD | 9 | 1.3 | II | NA | 2018 Jan 5 | 17 | KL25 | AMK, CXC | CIP | 69 | Alive |
KP0879 | Blood | M | SVD | 13 | 4.4 | III | NA | 2018 Mar 19 | 17 | KL25 | MEM | MEM | NA | NA |
KP2326 | Blood | F | A | 7 | 1.1 | I | NA | 2018 Dec 29 | 17 | KL25 | AMK, CXC | NA | 9 | Dead |
KP2201 | Blood | M | CS | 10 | 1.3 | I | NA | 2018 Nov 24 | 17 | KL25 | AMK, CXC | MEM, CIP | 42 | Alive |
KP2557 | Blood | M | SVD | 18 | 2.5 | I | NA | 2019 Feb 6 | 17 | KL25 | AMK, CXC | MEM | NA | Alive |
KP2455 | Blood | F | CS | 10 | NA | III | NA | 2019 Jan 20 | 17 | KL25 | AMK, CXC | CIP | 27 | Alive |
KP026 | Cot | II | 2017 Sep 21 | 17 | KL25 | |||||||||
KP040 | Cot | III | 2017 Sep 21 | 17 | KL25 | |||||||||
KP090 | Trolley handle | III | 2017 Sep 21 | 17 | KL25 |
*Blank spaces indicate not applicable. AB, antimicrobial drug; AMK, amikacin; BSI, bloodstream infections; CAZ, ceftazidime; CIP, ciprofloxacin; CS, cesarean section; CXC, cloxacillin; DOA, duration of admission; DOS, duration of stay before specimen collection; MOD, mode of delivery; MEM, meropenem; NA, not available; ST, multilocus sequence type.
Page created: June 30, 2020
Page updated: August 19, 2020
Page reviewed: August 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.